Last updated: February 20, 2026
What Are the Criteria for Patentability of Biopharmaceuticals in Poland?
Poll is a member of the European Patent Office (EPO) system, with patent laws aligned to European standards. Basic criteria include novelty, inventive step, and industrial applicability.
Novelty:
- Must be new; no disclosure of the invention before the filing date within the European or Polish patent registers, or through prior publication, use, or public disclosures.
- Prior disclosures from scientific publications, patents, or databases invalidate novelty.
Inventive Step:
- Not obvious to a person skilled in the field based on prior art.
- European Patent Convention (EPC) standards apply, emphasizing non-obviousness over technical and scientific background.
Industrial Applicability:
- The invention must have a specific, substantial, and credible utility.
Additional Polish specific considerations:
- Polish law excludes inventions that are contrary to ordre public or morality, which can affect biopharmaceutical patents.
- Methods of medical treatment are generally not patentable, but the products used in such methods may be.
How Does Enforceability of Biopharmaceutical Patents Function in Poland?
Polish patent enforcement aligns with EPC and EU regulations, emphasizing robust rights but also subject to specific limitations.
Key enforcement points include:
- Patent holders can initiate infringement proceedings in Polish courts.
- Enforcement involves cease and desist orders, damages, and, in some cases, injunctions.
- Validity challenges can be filed via invalidity actions or opposition procedures, typically within nine months of grant.
- Patent rights are valid for 20 years from the filing date, subject to annual maintenance fees.
Limitations:
- Medical use claims are often limited; enforcement against indirect infringing activities must consider the scope of claims and medical exemptions.
- The doctrine of equivalents is recognized but must be balanced with the disclosure of the patent's scope.
What Is the Scope of Claims for Biopharmaceutical Patents in Poland?
Claims determine the breadth of patent protection. In biopharmaceuticals, claims can cover compounds, formulations, methods of production, and uses.
Types of claims include:
- Compound claims: cover novel molecules, such as proteins, antibodies, or nucleic acids.
- Use claims: cover specific therapeutic applications. Patents cannot claim methods of medical treatment but can claim the use of compounds for treatment.
- Process claims: cover manufacturing methods, including recombinant DNA techniques.
Claim drafting considerations:
- Claims should be clear and supported by the description.
- Narrow claims focus on specific molecules or uses to ensure enforceability.
- Broad claims may face validity challenges unless well-supported and novel.
Scope limitations:
- Swiss-type and second medical use claims are permissible for new therapeutic uses of known compounds.
- Claims directed toward methods of treatment are generally not patentable unless formulated as pharmaceutical products or formulations.
Additional Considerations
- Polish law restricts patenting of inventions that involve biological material isolated from nature unless obtained through technical processes.
- The European Union’s bioethical rules influence patent scope, especially concerning gene editing and human embryonic material.
Summary Table
| Aspect |
Details |
| Patentability |
Novelty, inventive step, industrial applicability, subject to morality and ordre public. |
| Enforceability |
Court-based enforcement; patent validity can be challenged within nine months of grant. |
| Scope of Claims |
Covers compounds, uses, and production processes but restricts method-of-treatment claims. |
| Limitations |
Excludes methods of medical treatment from patentability; biological materials require technical process for patenting. |
Key Takeaways
- Poland’s patent system for biopharmaceuticals aligns with European standards, emphasizing novelty and inventive step.
- Patent claims should be specific and well-supported, especially for broad pharmaceutical compositions and uses.
- Enforcement relies on civil litigation, with patent validity able to be challenged within nine months of grant.
- Biological and medical method claims are generally excluded; focus on compounds, formulations, and industrial methods.
FAQs
-
Can I patent a new antibody in Poland?
Yes, if it is novel, inventive, and sufficiently described, antibody inventions can be patented under Polish law.
-
Are second medical use claims enforceable in Poland?
Yes, they are, provided they are drafted as Swiss-type or use claims specific to the new indication.
-
What are common reasons for patent invalidation in biopharmaceuticals?
Lack of novelty, obviousness, or insufficient disclosure are typical grounds. Biological inventions must demonstrate a technical process of isolation or modification.
-
How long does patent protection last for a biopharmaceutical in Poland?
20 years from the filing date, subject to annual maintenance fees.
-
Are biologics patentable in Poland?
Yes, provided they meet the criteria for patentability and are obtained through a technical process.
References
[1] European Patent Convention (EPC). European Patent Office.
[2] Polish Patent Law Act of 30 June 2000, Journal of Laws 2001 No. 49, item 546.
[3] Kluwer Patent Blog. "Patentability of biopharmaceuticals in Europe and Poland," 2022.
[4] European Commission. "Biotech patents and legal framework," 2022.
